> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AbbVie Abandons Alpha-Synuclein Parkinson’s Program
- URL: https://www.fdaweb.com/abbvie-abandons-alpha-synuclein-parkinsons-program/
- Published: 2022-04-20T12:00:00.000Z
- Updated: 2026-09-14T17:41:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151634

AbbVie has terminated its partnership with BioArctic AB to develop its portfolio of alpha-synuclein antibodies, including ABBV-0805 — a humanized monoclonal antibody targeting alpha-synuclein being investigated for treating Parkinson’s Disease. Their collaboration began in 2016 and in 2019 a Phase 1 study of ABBV-0805 was started. Results from the study were presented at the International Congress of Parkinson's Disease and Movement Disorders 9/2021, which BioArctic says “supports a continuation into Phase 2 with once-monthly dosing.” The Phase 1 study concluded that ABBV-0805 selectively targets soluble toxic α-synuclein oligomers with a “high affinity and demonstrates excellent *in vivo* efficacy,” according to the study abstract.

A disappointed BioArctic says that all available data indicate that ABBV-0805 has “uniquely high selectivity for the pathological forms of aggregated alpha-synuclein, as well as Phase 1 data supporting progression to Phase 2\. We believe that ABBV-0805 has the potential to become a disease-modifying treatment for people with Parkinson's disease and will now investigate options to continue the development of this asset.”